128 related articles for article (PubMed ID: 37401340)
1. Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature.
Ali SB; Vembar P; Sukumaran S; Gunawardane D; Hughes T; Smith A
Immunotherapy; 2023 Oct; 15(14):1125-1132. PubMed ID: 37401340
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
3. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
[TBL] [Abstract][Full Text] [Related]
4. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature.
Ozluk AA; Gunenc D; Yildirim SS; Karaca B
Melanoma Res; 2024 Apr; ():. PubMed ID: 38691011
[TBL] [Abstract][Full Text] [Related]
7. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
8. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
[TBL] [Abstract][Full Text] [Related]
9. Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion.
Ruini C; Haas C; Mastnik S; Knott M; French LE; Schlaak M; Berking C
J Immunother; 2021 Feb-Mar 01; 44(2):71-75. PubMed ID: 33323872
[TBL] [Abstract][Full Text] [Related]
10. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
Kubo T; Watanabe H; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Rai K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2020 Dec; 50(12):1447-1453. PubMed ID: 32869100
[TBL] [Abstract][Full Text] [Related]
12. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series.
Tew A; Khoja L; Pallan L; Steven N
J Oncol Pharm Pract; 2023 Jul; 29(5):1163-1171. PubMed ID: 35607278
[TBL] [Abstract][Full Text] [Related]
13. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
Sehgal K; Varkaris A; Viray H; VanderLaan PA; Rangachari D; Costa DB
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581048
[TBL] [Abstract][Full Text] [Related]
14. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
[TBL] [Abstract][Full Text] [Related]
16. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
Zhang L; Bai L; Liu X; Liu Y; Li S; Liu J; Zhang S; Yang C; Ren X; Cheng Y
Thorac Cancer; 2020 May; 11(5):1170-1179. PubMed ID: 32134200
[TBL] [Abstract][Full Text] [Related]
17. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
18. Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors.
Riveiro-Barciela M; Barreira-Díaz A; Vidal-González J; Muñoz-Couselo E; Martínez-Valle F; Viladomiu L; Mínguez B; Ortiz-Velez C; Castells L; Esteban R; Buti M
Liver Int; 2020 Aug; 40(8):1906-1916. PubMed ID: 32329119
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
Yomota M; Mirokuji K; Sakaguchi M; Kitahara Y; Chin F; Setoguchi K; Hosomi Y
Intern Med; 2021 Nov; 60(21):3459-3462. PubMed ID: 33775995
[TBL] [Abstract][Full Text] [Related]
20. Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy.
Burdett N; Hsu K; Xiong L; Tapia-Rico G; Beckmann K; Karapetis C; Brown MP
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e139-e145. PubMed ID: 31215775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]